Kigali facility revs up Africa’s vaccine self-reliance
A new European financial backing of BioNTech’s mRNA vaccine facility in Kigali marks a defining step in Africa’s long-term pursuit of health and industrial self-reliance, moving the continent’s vaccine manufacturing ambitions from concept to implementation. This month, on October 13, the European Investment Bank (EIB) and the European Commission announced a €95 million (approximately US$126 million) blended financing package to accelerate construction of BioNTech’s state-of-the-art mRNA vaccine manufacturing site in Rwanda. The package, comprising a €35 million (US$47 million) grant and up to €60 million (US$80 million) in loans, forms part of the EU’s Global Gateway strategy and builds on…
